Table 1.
Patient characteristics.
| Level 1 (Tocilizumab 4 mg/kg) | Level 2 (Tocilizumab 6 mg/kg) | Level 3 (Tocilizumab 8 mg/kg) | All patients | |
|---|---|---|---|---|
| Number of patients | 2 | 2 | 8 | 12 |
| Age (median, IQR) | 65.5 (65.2–65.8) | 69.0 (67.0–71.0) | 66.5 (65.0–70.5) | 66.0 (65.0–70.5) |
| Gender (n, %) (male/female) | 1/1 (50%/50%) | 0/2 (0%/100%) | 4/4 (50%/50%) | 5/7 (42%/58%) |
| ECOG | ||||
| 0 | 1 (50%) | 2 (100%) | 5 (62%) | 8 (67%) |
| 1 | 1 (50%) | 0 (0%) | 2 (25%) | 3 (25%) |
| 2 | 0 (0%) | 0 (0%) | 1 (12%) | 1 (8.3%) |
| ELN-2017 risk profile | ||||
| Intermediate | 1 (50%) | 1 (50%) | 1 (12%) | 3 (25%) |
| Defavorable | 1 (50%) | 1 (50%) | 7 (88%) | 9 (75%) |
| De novo AML | 1 (50%) | 2 (100%) | 5 (62%) | 8 (67%) |
| Secondary AML | 1 (50%) | 0 (0%) | 3 (38%) | 4 (33%) |
| First line | 2 (100%) | 2 (100%) | 8 (100%) | 12 (100%) |